UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | G | H | K | L | N | S | V | W
Number of items: 23.


Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178 - ?.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, PJ; Endicott, JA; Gibson, AE; (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110 - ?.


Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; Azzabi, A; (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259 - ?.


Calabrese, CR; Thomas, HD; Batey, MA; Boritzki, T; Zhang, K; White, AW; Curtin, NJ; (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543 - ?.

Calvert, AH; Ghokul, S; Al-Azraqi, A; Wright, J; Lind, M; Bailey, N; Highley, M; (1999) Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. SEMINARS IN ONCOLOGY , 26 (1) 90 - 94.

Calvert, AH; Hughes, AN; Calvert, PM; Plummer, RE; Highley, MS; (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146 - ?.

Calvert, AH; Sessa, C; Hughes, A; Jochim, U; Calvert, P; Ghielmini, M; Renard, J; (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147 - ?.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; Camboni, MG; (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333 - ?.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; Griffin, RJ; (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520 - ?.


Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; Calvert, AH; (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62 - ?.


Ghazal-Aswad, S; Tilby, MJ; Lind, M; Baily, N; Sinha, DP; Calvert, AH; Newell, DR; (1999) Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels. ANN ONCOL , 10 (3) 329 - 334.

Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564 - ?.


Hartley, JA; O'Hare, CC; Baumgart, J; (1999) DNA alkylation and interstrand cross-linking by treosulfan. BRIT J CANCER , 79 (2) 264 - 266.

Hughes, A; Calvert, H; (1999) An update on thymidylate synthase inhibitors. ANN ONCOL , 10 (10) 1137 - 1139.

Hughes, AN; Rafi, I; Griffin, MJ; Calvert, AH; Newell, DR; Calvete, JA; Johnston, A; (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. CLIN CANCER RES , 5 (1) 111 - 118.


Koberle, B; Masters, JRW; Hartley, JA; Wood, RD; (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. CURR BIOL , 9 (5) 273 - 276.


Leevers, SJ; Vanhaesebroeck, B; Waterfield, MD; (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. CURRENT OPINION IN CELL BIOLOGY , 11 (2) pp. 219-225. 10.1016/S0955-0674(99)80029-5.


Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124 - ?.


Smith, PG; Barlow, HC; Loughlin, P; Huang, B; Bowman, KJ; Calvert, AH; Curtin, NJ; (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82 - ?.

Smith, PG; Bewley, J; Gogel, JA; Calvert, AH; Newell, DR; Curtin, NJ; Chen, VJ; (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83 - ?.


Vanhaesebroeck, B; Waterfield, MD; (1999) Signaling by distinct classes of phosphoinositide 3-kinases. EXPERIMENTAL CELL RESEARCH , 253 (1) pp. 239-254. 10.1006/excr.1999.4701.


Webley, SD; Francis, R; Begent, RHJ; Hartley, JA; Hochhauser, D; (1999) Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 80 47 - 47.

This list was generated on Sun Oct 23 03:29:47 2016 BST.